secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001171843-25-004869
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor
---------------------------------------------------------------------------

- Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.
- Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.
- Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.
- Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.
- Stonehouse cited no disagreement; transition follows succession planning process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/0001171843-25-004869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004869/f8k_073125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer